TABLE 1

Patient characteristics

InformationHRA#LSNon-LSSA
BALF/serum/plasma12/12/00/8/612ƒ/12/012/12/00/20/0
Age years27±355±1642±743±949±11
Never-smokers/ex-smokers12/0NA8/39/317/3
Males/females12/07/612/012/01/19
Radiographic stage I/II/III/IVNANA5/6/0/03/9/0/0NA
FVC+ % of predicted114±11NA84±1690±14102±23
FEV1 % of predicted107±9NA86±1686±1582±20
FEV1/FVC§79±7NA78±770±669±9

Data are presented as n or mean±sd. For additional information, see supplementary table 1. H: healthy controls; RA: rheumatoid arthritis; LS: Löfgren's syndrome; SA: severe asthma; BALF: bronchoalveolar lavage fluid; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; NA: not available. #: information obtained from published data [13]. : stage I indicates granuloma formation in the hilar lymph nodes; stage II also has, in addition to the hilar lymphadenopathy, granuloma formation in the lung shown as diffuse infiltrates on the radiograph; stage III has parenchymal infiltrates on the radiograph but absence of hilar adenopathy; stage IV indicates irreversible pulmonary scarring. +: LS group is missing one value. §: LS group is missing one value; non-LS group is missing three values. ƒ: LS group contains two different BALF samples from the same patient.